Table 1.

Model inputs

	Base value (range)	Distribution in PSA	Source
Distribution of patients with PTSD who receive MDMA-AT by severity
Asymptomatic	33.3	NA	[24]
Mild	26.2	NA	[24]
Moderate	26.2	NA	[24]
Severe	11.9	NA	[24]
Extreme	2.4	NA	[24]
Dead	0	NA	[24]
Distribution of patients with PTSD who receive standard of care by severity
Asymptomatic	0	NA	[24]
Mild	0	NA	[24]
Moderate	0	NA	[24]
Severe	71.4	NA	[24]
Extreme	28.3	NA	[24]
Dead	0	NA	[24]
Costs (in 2020 US$)b
MDMA-AT (one-time)	11,537 (8076–14,998)	Gamma	[55, 56]a
Standard of care	0 (0–13,256)	Gamma	[55, 56]a
Medical care for asymptomatic PTSD	5032 (3608–6456)	Gamma	[57–60]a
Medical care for mild PTSD	10,118 (7250–12,986)	Gamma	[57–60]a
Medical care for moderate PTSD	15,177 (10,855–19,469)	Gamma	[57–60]a
Medical care for severe PTSD	20,236 (14,512–25,960)	Gamma	[57–60]a
Medical care for extreme PTSD	24,283 (17,415–31,151)	Gamma	[57–60]a
Health utilities
Asymptomatic	0.90 (0.81–0.99)	Beta	[24]
Mild	0.83 (0.75–0.91)	Beta	[24]
Moderate	0.74 (0.67–0.81)	Beta	[24]
Severe	0.61 (0.55–0.67)	Beta	[24]
Extreme	0.37 (0.33–0.41)	Beta	[24]
Dead	0	NA	Assumed
Other inputs and assumptions
Cohort size (range)	3,523,049 (2,110,743–4,735,640)	Normal	[16–18, 31–33]a
Annual discount rate (%)	3 (0.23–0.38)	Beta	Assumed
Time horizon (years)	30 (10–40)	Uniform	Assumed
Mean age of cohort	41	NA	[22]
Probability of death from all causes	0.002 (0.0018–0.0022)	Beta	[61]

MDMA-AT 3,4-methylenedioxymethamphetamine assisted-therapy, NA not applicable, PSA probabilistic sensitivity analysis, PTSD post-traumatic stress disorder

^aBase-case value and range calculated by authors using the references listed

^bCosts are annual unless otherwise noted